Following the completion of the sale, the chief executive officer now directly owns 334,833 shares in the company, valued at $46,916,799.96. The shares were sold at an average price of $140.12, for a total transaction of $39,571,008.96. Rusckowski sold 282,408 shares of the firm’s stock in a transaction that occurred on Tuesday, May 24th. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Following the sale, the director now directly owns 23,933 shares of the company’s stock, valued at $3,255,845.32. The shares were sold at an average price of $136.04, for a total value of $272,080.00. Ring sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, August 1st. The sale was disclosed in a legal filing with the SEC, which is available at this link. Following the sale, the chief executive officer now directly owns 334,833 shares of the company’s stock, valued at $46,916,799.96. The shares were sold at an average price of $140.12, for a total value of $39,571,008.96. Rusckowski sold 282,408 shares of the stock in a transaction dated Tuesday, May 24th. Insider Transactions at Quest Diagnostics

Quest Diagnostics’s payout ratio is 21.96%. The ex-dividend date is Monday, October 3rd. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.95%. Stockholders of record on Tuesday, October 4th will be issued a $0.66 dividend. The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 19th. Equities analysts forecast that Quest Diagnostics Incorporated will post 9.69 EPS for the current year. The company’s revenue for the quarter was down 3.8% on a year-over-year basis. During the same period in the prior year, the firm posted $3.18 earnings per share. The firm had revenue of $2.45 billion for the quarter, compared to the consensus estimate of $2.34 billion. Quest Diagnostics had a net margin of 14.02% and a return on equity of 24.62%. The medical research company reported $2.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.26 by $0.10. Quest Diagnostics ( NYSE:DGX – Get Rating) last announced its quarterly earnings results on Thursday, July 21st. The company has a 50-day moving average price of $135.42 and a two-hundred day moving average price of $136.37. Quest Diagnostics Incorporated has a twelve month low of $125.33 and a twelve month high of $174.16. The firm has a market capitalization of $15.80 billion, a PE ratio of 11.27 and a beta of 1.00. The company has a quick ratio of 1.42, a current ratio of 1.54 and a debt-to-equity ratio of 0.62. Shares of NYSE:DGX opened at $135.48 on Monday. Institutional investors own 89.89% of the company’s stock. now owns 21,679 shares of the medical research company’s stock valued at $2,966,000 after buying an additional 121 shares during the period. grew its position in Quest Diagnostics by 0.6% during the first quarter. Freestone Capital Holdings LLC now owns 2,025 shares of the medical research company’s stock valued at $350,000 after buying an additional 121 shares during the period. Freestone Capital Holdings LLC grew its position in Quest Diagnostics by 6.4% during the fourth quarter. Personal CFO Solutions LLC now owns 6,382 shares of the medical research company’s stock valued at $873,000 after buying an additional 103 shares during the period. Personal CFO Solutions LLC grew its position in Quest Diagnostics by 1.6% during the first quarter. now owns 5,288 shares of the medical research company’s stock worth $915,000 after acquiring an additional 102 shares in the last quarter. grew its stake in shares of Quest Diagnostics by 2.0% in the 4th quarter. now owns 13,838 shares of the medical research company’s stock worth $2,394,000 after acquiring an additional 100 shares in the last quarter. grew its stake in shares of Quest Diagnostics by 0.7% in the 4th quarter. Several other institutional investors have also recently made changes to their positions in the company. Aaron Wealth Advisors LLC owned approximately 0.05% of Quest Diagnostics at the end of the most recent reporting period. The institutional investor bought 61,176 shares of the medical research company’s stock, valued at approximately $447,000.

Aaron Wealth Advisors LLC bought a new position in Quest Diagnostics Incorporated ( NYSE:DGX – Get Rating) in the 1st quarter, according to the company in its most recent filing with the SEC.

Quest diagnostics appointments